作　　者： ; ; ; ;

机构地区： 东莞市虎门医院

出　　处： 《中国卫生标准管理》 2019年第17期97-99,共3页

摘　　要： 目的探讨Cyp2c19多态性对氯吡格雷治疗冠状动脉粥样硬化性心脏病疗效的临床意义。方法选取我院2016年1月-2017年10月120例非经皮冠状动脉介入治疗冠心病患者分为两组,分别是对照组和观察组。对照组使用氯吡格雷治疗。而观察组则在用药之前进行Cyp2c19基因检测,Cyp2c19 618GG型患者给予氯吡格雷,Cyp2c19618GA与AA型患者给予替格瑞洛进行治疗。在历时12个月的治疗以后,对不良心血管终点事件的发生率进行比较。结果观察组患者中Cyp2c19 618GA型22例、Cyp2c19 618GG型32例、Cyp2c19 618AA型6例,Cyp2c19 618A等位患者基因携带率为46.7%,观察组患者的出血率相较于对照组患者而言,观察组要优于对照组,差异存在统计学意义(P<0.05)。患者在经过治疗后,观察组患者的不良心血管终点事件发生率为11.7%,低于对照组的38.3%(P<0.05)。结论对于患者进行Cyp2c19基因检测之后,使用氯吡格雷可以有效地降低治疗PCI冠心病患者的不良心血管终点事件的发生率。 Objective To investigate the clinical significance of Cyp2 c19 polymorphism in the treatment of coronary atherosclerotic heart disease with clopidogrel. Methods 120 patients with coronary heart disease undergoing non-percutaneous coronary intervention from January 2016 to October 2017 were selected and divided into two groups, the control group and the observation group respectively. The control group was treated with clopidogrel. The observation group was tested for Cyp2 c19 gene before taking drugs. Patients with Cyp2 c19 618 GG type were treated with clopidogrel, while patients with Cyp2 c19 618 GA and AA type were treated with tigrew. After 12 months of treatment, the incidence of unconscionable vascular endpoint events was compared. Results in the observation group, there were 22 cases of Cyp2 c19 618 GA type, 32 cases of Cyp2 c19 618 GG type and 6 cases of Cyp2 c19 618 AA type. the gene carrying rate of Cyp2 c19 618 A allele was 46.7%. compared with the control group, the bleeding rate of the observation group was better than that of the control group, and the difference was statistically significant(P < 0.05). After treatment, the incidence of unconscionable vascular endpoint events in the observation group was 11.7%, lower than 38.3% in the control group(P < 0.05). Conclusion After Cyp2 c19 gene detection for patients, clopidogrel can effectively reduce the incidence of unconscionable vascular endpoint events in PCI patients with coronary heart disease.

关 键 词： 冠状动脉粥样硬化性心脏病 氯吡格雷 临床意义 冠状动脉 基因检测

领　　域： []